BC Innovations | Jul 20, 2017
Product R&D

Eureka moment for TCR mimics

In the race to access the wealth of intracellular molecular targets once considered undruggable, Eureka Therapeutics Inc. is pioneering TCR -like antibodies that capitalize on the ability of TCRs to recognize tumor antigens. But the...
BC Innovations | Oct 22, 2015
Distillery Therapeutics

Therapeutics: Wilms tumor 1 (WT1); CD3e molecule epsilon (CD3-TCR complex)(CD3ε; CD3E)

Cancer INDICATION: Cancer; leukemia Cell culture and mouse studies suggest a bispecific T cell engager (BiTE) antibody targeting WT1 and CD3ε could help treat cancer and leukemia. The BiTE consisted of ESK1 - which is a...
BC Extra | Sep 24, 2014
Financial News

Eureka raises $21M in C round

Cancer company Eureka Therapeutics Inc. (Emeryville, Calif.) raised $21 million in an untranched series C round led by new investor Yuan Capital. Additional new investor Majuven and existing investors Acorn Campus Ventures, Suma Venture and...
BC Week In Review | Feb 3, 2014
Company News

Eureka Therapeutics, Novartis, Memorial Sloan Kettering deal

Eureka and Memorial Sloan Kettering Cancer Center granted Novartis exclusive, worldwide rights to develop and commercialize ESK1 , a preclinical mAb against Wilm's Tumor 1 ( WT1 ) in development for cancer. Eureka and the center will receive...
BC Extra | Jan 29, 2014
Company News

Novartis in-licenses WT1 mAb

Eureka Therapeutics Inc. (Emeryville, Calif.) and Memorial Sloan Kettering Cancer Center granted Novartis AG (NYSE:NVS; SIX:NOVN) exclusive, worldwide rights to develop and commercialize ESK1, a preclinical mAb against Wilm's Tumor 1 ( WT1 ) in development for...
BC Innovations | Mar 28, 2013
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Leukemia; solid tumors Human leukocyte antigen (HLA); Wilms tumor 1 (WT1) Mouse and cell culture studies suggest a human mAb targeting the WT1-HLA complex could...
BC Innovations | Mar 28, 2013
Targets & Mechanisms

mAb attack on WT1

Wilms tumor 1 is overexpressed in many different cancers, but most antibody and small molecule developers have deemed it undruggable because it is an intracellular transcription factor. Now, researchers at Eureka Therapeutics Inc. and the...
Items per page:
1 - 7 of 7